NO20072494L - Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid - Google Patents

Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid

Info

Publication number
NO20072494L
NO20072494L NO20072494A NO20072494A NO20072494L NO 20072494 L NO20072494 L NO 20072494L NO 20072494 A NO20072494 A NO 20072494A NO 20072494 A NO20072494 A NO 20072494A NO 20072494 L NO20072494 L NO 20072494L
Authority
NO
Norway
Prior art keywords
donepezil hydrochloride
solid pharmaceutical
pharmaceutical compound
relates
composition
Prior art date
Application number
NO20072494A
Other languages
English (en)
Norwegian (no)
Inventor
Rok Zupet
Matej Rkolj
Miha Vrbinc
Berta Kotar-Jordan
Original Assignee
Krka Tovarna Zdravil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35464350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072494(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka Tovarna Zdravil filed Critical Krka Tovarna Zdravil
Publication of NO20072494L publication Critical patent/NO20072494L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
NO20072494A 2004-10-19 2007-05-15 Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid NO20072494L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004051055 2004-10-19
PCT/EP2005/011249 WO2006045512A1 (en) 2004-10-19 2005-10-19 Solid pharmaceutical composition comprising donepezil hydrochloride

Publications (1)

Publication Number Publication Date
NO20072494L true NO20072494L (no) 2007-07-02

Family

ID=35464350

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072494A NO20072494L (no) 2004-10-19 2007-05-15 Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid

Country Status (19)

Country Link
US (3) US20090130205A9 (de)
EP (3) EP2283811A1 (de)
JP (1) JP2008517022A (de)
AT (1) ATE415148T1 (de)
CA (1) CA2584547C (de)
CY (1) CY1109956T1 (de)
DE (1) DE602005011326D1 (de)
DK (1) DK1811957T3 (de)
EA (1) EA012220B1 (de)
ES (1) ES2317313T3 (de)
HR (1) HRP20090104T3 (de)
NO (1) NO20072494L (de)
PL (1) PL1811957T3 (de)
PT (1) PT1811957E (de)
RS (1) RS51271B (de)
SI (1) SI1811957T1 (de)
UA (1) UA83152C2 (de)
WO (1) WO2006045512A1 (de)
ZA (1) ZA200704023B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515803D0 (en) * 2005-07-30 2005-09-07 Pliva Hrvatska D O O Intermediate compounds
DE102005060377A1 (de) * 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
EP2037918A2 (de) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Pharmazeutische pimavanserin-formulierungen
GB0614586D0 (en) * 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
AU2008207864B2 (en) * 2007-01-24 2013-07-11 Cook Biotech Incorporated Biofilm-inhibiting medical products
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
DE102007037932A1 (de) * 2007-08-11 2009-02-12 Alfred E. Tiefenbacher Gmbh & Co.Kg Donepezilhydrochlorid in amorpher Form enthaltende Tablette
DE102009041839A1 (de) * 2009-09-18 2011-03-24 Dolorgiet Gmbh & Co. Kg Donepezil-haltige Tabletten
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (de) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Donepezilformulierungen mit verzögerter Freisetzung
DE102010010998A1 (de) * 2010-03-10 2011-09-15 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung, umfassend Donepezil-Hydrochlorid der kristallinen polymorphen Form I
WO2012016708A1 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
SG10201602111VA (en) * 2010-11-30 2016-04-28 Wista Lab Ltd Formulations Comprising Methylthioninium Chloride
EP2502620A1 (de) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Feste pharmazeutische Zusammensetzung mit Donepezil
US20150216849A1 (en) 2014-02-04 2015-08-06 Forest Laboratories Holdings Ltd. Donepezil compositions and methods of treating alzheimers disease
CN114272219B (zh) * 2021-12-30 2023-11-10 江苏豪森药业集团有限公司 一种盐酸多奈哌齐片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
RU2190603C2 (ru) 1996-06-07 2002-10-10 Эйсай Ко., Лтд. Полиморфные модификации донепезила гидрохлорида, способы их получения и способ лечения заболевания, сопровождающегося активностью ацетилхолинэстеразы
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
AU1153097A (en) * 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
EP1017823B1 (de) * 1997-02-07 2004-07-14 Princeton University Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
CZ300064B6 (cs) * 1998-02-19 2009-01-21 Sapporo Breweries Limited Nukleová kyselina kódující protein, vektor, rostlinná bunka, zpusob prípravy transformovaných rostlinných bunek, primer nukleové kyseliny a souprava pro detekci regulacních sekvencí
WO2000059544A1 (en) * 1999-03-31 2000-10-12 Eisai Co., Ltd. Stabilized compositions containing nootropic drugs
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1260215E (pt) * 2000-03-01 2009-09-03 Eisai R&D Man Co Ltd Comprimido de desintegração rápida que contém poli(álcool vinílico)
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IN192180B (de) * 2001-09-28 2004-03-06 Ranbaxy Lab
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
AU2003280324A1 (en) * 2002-11-26 2004-06-18 Alk-Abello A/S Pharmaceutical allergen product
WO2004092137A1 (en) * 2003-04-16 2004-10-28 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics

Also Published As

Publication number Publication date
EP2039349A1 (de) 2009-03-25
DE602005011326D1 (de) 2009-01-08
JP2008517022A (ja) 2008-05-22
EA200700673A1 (ru) 2007-10-26
US20120283291A1 (en) 2012-11-08
EP1811957A1 (de) 2007-08-01
PL1811957T3 (pl) 2009-05-29
CY1109956T1 (el) 2014-09-10
US20100317694A1 (en) 2010-12-16
SI1811957T1 (sl) 2009-04-30
US20090130205A9 (en) 2009-05-21
ZA200704023B (en) 2008-04-30
CA2584547A1 (en) 2006-05-04
HRP20090104T3 (hr) 2009-03-31
UA83152C2 (ru) 2008-06-10
EA012220B1 (ru) 2009-08-28
CA2584547C (en) 2014-07-08
ATE415148T1 (de) 2008-12-15
RS51271B (sr) 2010-12-31
ES2317313T3 (es) 2009-04-16
PT1811957E (pt) 2009-01-27
EP2283811A1 (de) 2011-02-16
WO2006045512A1 (en) 2006-05-04
EP1811957B1 (de) 2008-11-26
DK1811957T3 (da) 2009-03-30
US20080063705A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
NO20072494L (no) Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid
DK1707562T3 (da) Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne
NO20080243L (no) Substituerte arylpyrazoler til anvendelse mot parasitter
DK1695710T3 (da) Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
EA200970051A1 (ru) Антагонист рецептора il-8
NO20080784L (no) Histondeacetylaseinhibitorer
CL2009001993A1 (es) Compuestos derivados de 6-oxo-4-fenilamino-1,6-dihidropiridina-3-amida, inhibidores de mek; proceso de preparacion de estos, utiles en el tratamiento de un trastorno hiperproliferativo o una condicion inflamatoria. (divisional de la solicitud cl 1168-06)
WO2004074438A3 (en) Ccr8 antagonists
DK1695965T3 (da) Krystallinsk betaform af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famceutiske sammensætninger indeholdende denne
NO20063501L (no) Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese
WO2004073619A3 (en) Ccr8 antagonists
NO20084583L (no) Makrosykliske kinase-inhibitorer
DK1695709T3 (da) Krystalinsk gammad-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
NO20074874L (no) Amorf lerkanidipinhydroklorid
ATE465719T1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
WO2007030361A3 (en) Benzimidazole thiophene compounds as plk inhibitors
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
DK2407451T3 (da) N,N-substituerede 3-aminopyrrolidin-forbindelser anvendelige som monoamin-genoptagelseshæmmere
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
NO20064034L (no) Makrolider og fremgangsmater for a fremstille disse
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
PH12021550456A1 (en) Crystalline forms of a quinazole compound and its hydrochloride salts
TW200833371A (en) Process for solid formulations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application